An interventional study of intermittent Theta Burst Stimulation in Treatment Resistant Depression, sponsored by University of Pennsylvania. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.
Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 88th largest by planned enrollment of the 181 interventional ones that give a count, is one of 15 that started in 2020, is one of 72 with no phase, reaches primary completion later than 15 of the 64 other live ones, and was the 114th registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:
NeuroRx, Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 22–60
Motif Neurotech, Inc. · Sites in United States
Ages 22–85
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
Mclean Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 58 · Phase 3 23 · Phase 4 17
First in 2001; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 38 across the 181 interventional studies, 66 across the 23 observational. Of the 120 that completed or were terminated, 70 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 205 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 2 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
20 of the studies in Depressive Disorder, Treatment-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT04684706University of PennsylvaniaCompressed Intermittent Theta Burst Stimulation | 2026-11-30 |
| NCT06938841University of California, San DiegoMaintenance rTMS for Depression (Maitr-De) | 2026-11-30 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this proposal the investigators will use an accelerated TMS protocol that concentrates the magnetic stimulation that would usually occur over 6 weeks into 10 treatment sessions per days, for 5 consecutive days in patient with treatment-refractory depression. This protocol will build on a previously published study demonstrating clinical efficacy of intermittent theta-burst stimulation (iTBS) on left dorsolateral prefrontal cortex (L-dlPFC) in a treatment refractory population.
Major depressive disorder (MDD) is a disabling mental disorder with a lifetime prevalence of up to16% . Approximately 30% of MDD patients suffer treatment resistant depression (TRD), with at least 2 failed adequate trials of pharmacotherapy. Repetitive transcranial magnetic stimulation (rTMS) has been shown to be a safe treatment for TRD, yet the standard clinical technique for using it as treatment depressive disorders is associated with limited efficacy to date. Among the potential causes of limited efficacy have been the scalp based targeting technique that is currently the most common targeting method rather than techniques that incorporate functional magnetic resonance imaging (fMRI) neuronavigation, which have been shown to have greater efficacy. Image guided TMS can target specific functional brain networks with greater resolution that takes into account individual differences in brain anatomy.
Another technique for improving treatment efficacy, shown to modulate cortical excitability, may be the application of intermittent theta-burst stimulation in regular intervals, which has been shown to be no different than a longer-in-time application of rTMS. Paired with the evidence that iTBS has produced significant antidepressant responses in severely depressed individuals, and that relapse in depressive states predicts diminished efficacy of treatment as well as increased quantity of TBS pulses to have a beneficial effect, these recent iTBS findings suggest that iTBS may offer a valid treatment alternative to options that have proven otherwise ineffective in treating TRD. Therefore, the investigators aim to administer iTBS to severely-depressed participant in a shorter amount of time, in order to improve their antidepressant outcome.
Significance: This protocol builds on different notions:
Therefore, the compression of iTBS pulses with shorter intervals between sessions is hypothesized to have an increased beneficial effect on individuals affected by treatment-resistant depression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stimulation 3-pulse 50-Hz bursts at 5-Hz for 2-s trains, with trains every 10 s, for 10 minutes, 10 times a day, for 5 consecutive days.
Device: intermittent Theta Burst Stimulation
The present study will utilize TMS dosage of iTBS of 18 000 pulses a day for 5 consecutive days.
Depressive Symptoms Change
Depressive symptoms will be measured before and after treatment by means of the clinician-administered Montgomery Asberg Depression Rating Scale (MADRS) (0-60, lower scores indicate lower depressive symptoms) and the self report Beck Depression Inventory (BDI II) (0-30, lower scores indicate lower depressive symptoms). Change will be measured by comparing measurements pre- and post- on the same measures. The bigger the change, the bigger the reduction in depressive symptoms.
Time frame: 2 Weeks
Self report Symptom Change
Depressive symptoms will be measured before and after treatment by means of the self report Beck Depression Inventory (BDI II) (0-30, lower scores indicate lower depressive symptoms). Change will be measured by comparing measurements pre- and post- on the same measures. The bigger the change, the bigger the reduction in depressive symptoms.
Time frame: 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Nov 2026, 81 months after the start.
Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 81 months is above that.
Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →